The addition of Epcoritamab to the NCCN Clinical Practice Guidelines in Oncology for B-Cell Lymphomas indicates that the treatment is recognized as a valuable option for patients. This may lead to increased adoption of the treatment, resulting in higher revenues for Genmab and a potential positive impact on the company's stock price.